Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 4Phase EARLY_PHASE1 2Phase 4 2Phase 1/2 2Phase 3 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 457Pancreatic Neoplasms 364Stomach Neoplasms 246Carcinoma, Hepatocellular 231Carcinoma, Non-Small-Cell Lung 165Colonic Neoplasms 146Esophageal Neoplasms 133Neoplasms 115Neoplasm Metastasis 115Ovarian Neoplasms 111Rectal Neoplasms 107Liver Neoplasms 101Breast Neoplasms 99Lung Neoplasms 79Melanoma 76Squamous Cell Carcinoma of Head and Neck 70Gastrointestinal Neoplasms 58Endometrial Neoplasms 58Carcinoma, Renal Cell 54Uterine Cervical Neoplasms 52Cholangiocarcinoma 52Biliary Tract Neoplasms 52Triple Negative Breast Neoplasms 49Head and Neck Neoplasms 48Sarcoma 46Prostatic Neoplasms 45Esophageal Squamous Cell Carcinoma 39Urinary Bladder Neoplasms 34Small Cell Lung Carcinoma 31Carcinoma 29

Interventions

Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Cancer Non-resectable × Gastrointestinal × Clear all
NCT07575191 2026-05-08

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

Smartwise Sweden AB

Phase 1/2 Not yet recruiting
9 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT03165591 2019-08-30

V3-P

Immunitor LLC

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡